Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04DJN
|
|||
| Former ID |
DNC002525
|
|||
| Drug Name |
Dihydrotestosterone
|
|||
| Synonyms |
Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate hyperplasia [ICD-11: GA90; ICD-10: N40] | Phase 4 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H30O2
|
|||
| Canonical SMILES |
CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C
|
|||
| InChI |
1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
|
|||
| InChIKey |
NVKAWKQGWWIWPM-ABEVXSGRSA-N
|
|||
| CAS Number |
CAS 521-18-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6646, 76024, 583926, 583927, 583928, 583929, 583930, 583932, 583933, 583934, 585358, 585359, 585360, 585692, 824234, 836816, 838818, 841438, 7887032, 7979089, 8145454, 8157682, 11532131, 12146093, 14751321, 14751322, 17389515, 24702282, 24891337, 25621350, 26707661, 26737076, 26737079, 26737083, 26737086, 26737089, 26737091, 26737094, 26737096, 26737098, 26737108, 26737500, 29229109, 38671806, 46392350, 46393206, 46393207, 46393212, 46518267, 48421870
|
|||
| ChEBI ID |
CHEBI:16330
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Androgen receptor (AR) | Target Info | Modulator | [3] |
| Androgen receptor messenger RNA (AR mRNA) | Target Info | Agonist | [4] | |
| KEGG Pathway | Oocyte meiosis | |||
| Pathways in cancer | ||||
| Prostate cancer | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| AndrogenReceptor Signaling Pathway | ||||
| FSH Signaling Pathway | ||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Coregulation of Androgen receptor activity | ||||
| Regulation of Androgen receptor activity | ||||
| Nongenotropic Androgen signaling | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| FOXA1 transcription factor network | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Integrated Pancreatic Cancer Pathway | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Nuclear Receptors | ||||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2856). | |||
| REF 2 | ClinicalTrials.gov (NCT00062790) Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels. U.S. National Institutes of Health. | |||
| REF 3 | Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.